MSF experiences of providing multidisciplinary primary level NCD care for Syrian refugees and the host population in Jordan: an implementation study guided by the RE-AIM framework.
Cardiovascular disease
Conflict
Diabetes
Effectiveness
Evaluation
Humanitarian
Hypertension
Implementation
Jordan
Non communicable disease
Programme
RE-AIM
Refugee
Syria
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
26 Apr 2021
26 Apr 2021
Historique:
received:
31
01
2020
accepted:
30
03
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
15
5
2021
Statut:
epublish
Résumé
In response to the rising global NCD burden, humanitarian actors have rapidly scaled-up NCD services in crisis-affected low-and-middle income countries. Using the RE-AIM implementation framework, we evaluated a multidisciplinary, primary level model of NCD care for Syrian refugees and vulnerable Jordanians delivered by MSF in Irbid, Jordan. We examined the programme's Reach, Effectiveness, Adoption and acceptance, Implementation and Maintenance over time. This mixed methods retrospective evaluation, undertaken in 2017, comprised secondary analysis of pre-existing cross-sectional household survey data; analysis of routine cohort data from 2014 to 2017; descriptive costing analysis of total annual, per-patient and per-consultation costs for 2015-2017 from the provider-perspective; a clinical audit; a medication adherence survey; and qualitative research involving thematic analysis of individual interviews and focus group discussions. The programme enrolled 23% of Syrian adult refugees with NCDs in Irbid governorate. The cohort mean age was 54.7 years; 71% had multi-morbidity and 9.9% self-reported a disability. The programme was acceptable to patients, staff and stakeholders. Blood pressure and glycaemic control improved as the programme matured and by 6.6 mmHg and 1.12 mmol/l respectively within 6 months of patient enrolment. Per patient per year cost increased 23% from INT$ 1424 (2015) to 1751 (2016), and by 9% to 1904 (2017). Cost per consultation increased from INT$ 209 to 253 (2015-2017). Staff reported that clinical guidelines were usable and patients' self-reported medication adherence was high. Individual, programmatic and organisational challenges to programme implementation and maintenance included the impact of war and the refugee experience on Syrian refugees' ability to engage; inadequate low-cost referral options; and challenges for MSF to rapidly adapt to operating in a highly regulated and complex health system. Essential programme adaptations included refinement of health education, development of mental health and psychosocial services and addition of essential referral pathways, home visit, physiotherapy and social worker services. RE-AIM proved a valuable tool in evaluating a complex intervention in a protracted humanitarian crisis setting. This multidisciplinary programme was largely acceptable, achieving good clinical outcomes, but for a limited number of patients and at relatively high cost. We propose that model simplification, adapted procurement practices and use of technology could improve cost effectiveness without reducing acceptability, and may facilitate replication.
Sections du résumé
BACKGROUND
BACKGROUND
In response to the rising global NCD burden, humanitarian actors have rapidly scaled-up NCD services in crisis-affected low-and-middle income countries. Using the RE-AIM implementation framework, we evaluated a multidisciplinary, primary level model of NCD care for Syrian refugees and vulnerable Jordanians delivered by MSF in Irbid, Jordan. We examined the programme's Reach, Effectiveness, Adoption and acceptance, Implementation and Maintenance over time.
METHODS
METHODS
This mixed methods retrospective evaluation, undertaken in 2017, comprised secondary analysis of pre-existing cross-sectional household survey data; analysis of routine cohort data from 2014 to 2017; descriptive costing analysis of total annual, per-patient and per-consultation costs for 2015-2017 from the provider-perspective; a clinical audit; a medication adherence survey; and qualitative research involving thematic analysis of individual interviews and focus group discussions.
RESULTS
RESULTS
The programme enrolled 23% of Syrian adult refugees with NCDs in Irbid governorate. The cohort mean age was 54.7 years; 71% had multi-morbidity and 9.9% self-reported a disability. The programme was acceptable to patients, staff and stakeholders. Blood pressure and glycaemic control improved as the programme matured and by 6.6 mmHg and 1.12 mmol/l respectively within 6 months of patient enrolment. Per patient per year cost increased 23% from INT$ 1424 (2015) to 1751 (2016), and by 9% to 1904 (2017). Cost per consultation increased from INT$ 209 to 253 (2015-2017). Staff reported that clinical guidelines were usable and patients' self-reported medication adherence was high. Individual, programmatic and organisational challenges to programme implementation and maintenance included the impact of war and the refugee experience on Syrian refugees' ability to engage; inadequate low-cost referral options; and challenges for MSF to rapidly adapt to operating in a highly regulated and complex health system. Essential programme adaptations included refinement of health education, development of mental health and psychosocial services and addition of essential referral pathways, home visit, physiotherapy and social worker services.
CONCLUSION
CONCLUSIONS
RE-AIM proved a valuable tool in evaluating a complex intervention in a protracted humanitarian crisis setting. This multidisciplinary programme was largely acceptable, achieving good clinical outcomes, but for a limited number of patients and at relatively high cost. We propose that model simplification, adapted procurement practices and use of technology could improve cost effectiveness without reducing acceptability, and may facilitate replication.
Identifiants
pubmed: 33896418
doi: 10.1186/s12913-021-06333-3
pii: 10.1186/s12913-021-06333-3
pmc: PMC8074194
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
381Subventions
Organisme : Medecins Sans Frontieres UK
ID : n/a
Références
PLoS One. 2016 Apr 13;11(4):e0150088
pubmed: 27073930
BMC Public Health. 2015 Oct 31;15:1097
pubmed: 26521231
Glob Public Health. 2018 Feb;13(2):227-233
pubmed: 27141922
Anatol J Cardiol. 2016 Aug;16(8):554-62
pubmed: 27515102
Confl Health. 2017 Jul 17;11:14
pubmed: 28725259
Trop Med Int Health. 2012 Dec;17(12):1569-76
pubmed: 23051859
Confl Health. 2019 Mar 22;13:8
pubmed: 30949232
Front Public Health. 2019 Mar 29;7:64
pubmed: 30984733
BMJ. 2001 Feb 24;322(7284):444-5
pubmed: 11222407
JMIR Mhealth Uhealth. 2017 Oct 18;5(10):e158
pubmed: 29046266
Heart. 2019 Sep;105(18):1382-1383
pubmed: 31154428
Confl Health. 2019 Aug 9;13:37
pubmed: 31413727
Health Policy Plan. 2020 Oct 1;35(8):931-940
pubmed: 32621490
BMJ Open. 2016 Nov 30;6(11):e013375
pubmed: 27903564
Lancet. 2014 Jan 25;383(9914):356-67
pubmed: 24452044
Confl Health. 2017 Sep 17;11:17
pubmed: 28932259
PLoS Med. 2013;10(1):e1001377
pubmed: 23382655
Lancet. 2017 Nov 18;390(10109):2287-2296
pubmed: 28602563
PLoS Med. 2016 Nov 8;13(11):e1002180
pubmed: 27824879
BMJ Open. 2019 Nov 24;9(11):e030176
pubmed: 31767582
Prev Chronic Dis. 2018 Jan 04;15:E02
pubmed: 29300695
BMJ Open Diabetes Res Care. 2019 Aug 18;7(1):e000624
pubmed: 31497303
J Eval Clin Pract. 2011 Apr;17(2):371-2
pubmed: 21087371
Trop Med Int Health. 2014 Feb;19(2):219-23
pubmed: 24341942
Confl Health. 2020 Sep 1;14:63
pubmed: 32905304
PLoS Med. 2021 Jan 11;18(1):e1003279
pubmed: 33428612
Lancet. 2019 Oct 5;394(10205):1231-1242
pubmed: 31488369
Confl Health. 2019 Apr 2;13:12
pubmed: 30976298
East Mediterr Health J. 2018 Apr 05;24(1):92-98
pubmed: 29658625
Syst Rev. 2015 Nov 08;4:155
pubmed: 26547687
PLoS One. 2015 Sep 25;10(9):e0138303
pubmed: 26406317
Am J Public Health. 2013 Jun;103(6):e38-46
pubmed: 23597377
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Health Policy Plan. 2014 Sep;29(6):784-94
pubmed: 23958628
Value Health. 2014 Nov;17(7):A593
pubmed: 27202032
Prev Med Rep. 2018 Dec 13;13:160-165
pubmed: 30596007
BMC Health Serv Res. 2017 Jun 23;17(1):431
pubmed: 28645279
Trop Med Int Health. 2008 Oct;13(10):1225-34
pubmed: 18937743
J Trop Med. 2012;2012:137460
pubmed: 23056058
Trop Med Int Health. 2012 Sep;17(9):1163-70
pubmed: 22845700
Lancet Oncol. 2014 Jun;15(7):e290-7
pubmed: 24872112
World J Diabetes. 2016 Oct 15;7(18):462-469
pubmed: 27795820
Confl Health. 2019 Jun 13;13:26
pubmed: 31210780
Confl Health. 2018 Jul 11;12:33
pubmed: 30008800
Lancet Diabetes Endocrinol. 2019 Aug;7(8):638-647
pubmed: 30878268